PL372425A1 - Pochodne III dihydrobenzodiazepin-2-onu - Google Patents

Pochodne III dihydrobenzodiazepin-2-onu

Info

Publication number
PL372425A1
PL372425A1 PL03372425A PL37242503A PL372425A1 PL 372425 A1 PL372425 A1 PL 372425A1 PL 03372425 A PL03372425 A PL 03372425A PL 37242503 A PL37242503 A PL 37242503A PL 372425 A1 PL372425 A1 PL 372425A1
Authority
PL
Poland
Prior art keywords
dihydrobenzodiazepin
derivatives
treatment
neurological disorders
neurological
Prior art date
Application number
PL03372425A
Other languages
English (en)
Inventor
Geo Adam
Erwin Goetschi
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL372425A1 publication Critical patent/PL372425A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL03372425A 2002-02-06 2003-01-28 Pochodne III dihydrobenzodiazepin-2-onu PL372425A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02002012 2002-02-06

Publications (1)

Publication Number Publication Date
PL372425A1 true PL372425A1 (pl) 2005-07-25

Family

ID=27675598

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372425A PL372425A1 (pl) 2002-02-06 2003-01-28 Pochodne III dihydrobenzodiazepin-2-onu

Country Status (30)

Country Link
US (1) US6949542B2 (pl)
EP (1) EP1474416B1 (pl)
JP (1) JP4077411B2 (pl)
KR (1) KR20040081486A (pl)
CN (1) CN100497333C (pl)
AR (1) AR038481A1 (pl)
AT (1) ATE374196T1 (pl)
AU (1) AU2003205695B8 (pl)
BR (1) BR0307474A (pl)
CA (1) CA2474219C (pl)
DE (1) DE60316538T2 (pl)
DK (1) DK1474416T3 (pl)
ES (1) ES2294264T3 (pl)
GT (1) GT200300028A (pl)
HR (1) HRP20040678A2 (pl)
IL (1) IL163102A (pl)
MX (1) MXPA04007516A (pl)
MY (1) MY176608A (pl)
NO (1) NO327697B1 (pl)
NZ (1) NZ534122A (pl)
PA (1) PA8565901A1 (pl)
PE (1) PE20031011A1 (pl)
PL (1) PL372425A1 (pl)
PT (1) PT1474416E (pl)
RU (1) RU2315764C2 (pl)
SI (1) SI1474416T1 (pl)
TW (1) TWI326599B (pl)
UY (1) UY27654A1 (pl)
WO (1) WO2003066623A1 (pl)
ZA (1) ZA200406032B (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261945T1 (de) 1999-10-15 2004-04-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
ATE374030T1 (de) * 2003-07-25 2007-10-15 Hoffmann La Roche Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
ES2340321T3 (es) 2005-09-27 2010-06-01 F.Hoffmann-La Roche Ag Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2.
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
BRPI0810655A2 (pt) * 2007-04-19 2014-11-04 Hoffmann La Roche Derivados de di-hidro-benzo[b][1,4] diazepin-2-ona sulfonamida
BRPI0815696A2 (pt) 2007-08-27 2016-06-21 Hoffmann La Roche composto derivados de benzimidazol, processo para a sua manufatura, composições farmacêuticas que os compreendem, metódo para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de fxr e uso destes compostos.
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
BRPI0817101A2 (pt) 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
ES2409215T3 (es) 2007-09-14 2013-06-25 Janssen Pharmaceuticals, Inc. 4-fenil-1H-piridin-2-onas 1-3-disustituidas
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
AU2009279787B2 (en) 2008-08-04 2014-05-29 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
ES2401691T3 (es) 2008-11-28 2013-04-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2011021676A1 (ja) 2009-08-21 2011-02-24 大塚製薬株式会社 ベンゾ［ｂ］［１，４］ジアゼピン－２，４－ジオン化合物の製造方法
TWI481601B (zh) 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
EP2528441A4 (en) 2010-01-25 2013-07-10 Chdi Foundation Inc CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2701699B1 (en) * 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2013033246A2 (en) 2011-08-29 2013-03-07 Braincells, Inc. Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
JP2014525443A (ja) 2011-08-30 2014-09-29 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物、およびこれらの使用方法
US9981918B2 (en) 2011-08-30 2018-05-29 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
KR20150070187A (ko) 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 ｍｇｌｕ２／３ 길항제
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR20160143853A (ko) 2014-04-23 2016-12-14 에프. 호프만-라 로슈 아게 지적 장애의 치료를 위한 mglu2/3 길항제
WO2015191630A1 (en) * 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
KR20170026633A (ko) 2014-07-17 2017-03-08 씨에이치디아이 파운데이션, 인코포레이티드 Hiv-관련 장애의 치료 방법 및 치료용 조성물
JP2017206438A (ja) * 2014-08-22 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ［１，５−ｄ］［１，４］オキサゼピン化合物（ＴＥＴＲＡＨＹＤＲＯＩＭＩＤＡＺＯ［１，５−ｄ］［１，４］ＯＸＡＺＥＰＩＮＥＣＯＭＰＯＵＮＤ）
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
US12128018B2 (en) 2018-01-12 2024-10-29 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389189B1 (en) * 1989-03-23 1994-05-18 Pfizer Limited Diazepine antiallergy agents
ATE250039T1 (de) 1999-10-15 2003-10-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
ATE261945T1 (de) 1999-10-15 2004-04-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten

Also Published As

Publication number Publication date
RU2004126945A (ru) 2005-06-27
CN1633430A (zh) 2005-06-29
KR20040081486A (ko) 2004-09-21
PT1474416E (pt) 2007-12-27
UY27654A1 (es) 2003-08-29
ES2294264T3 (es) 2008-04-01
NZ534122A (en) 2006-12-22
IL163102A (en) 2011-07-31
JP2005522440A (ja) 2005-07-28
GT200300028A (es) 2004-06-11
EP1474416B1 (en) 2007-09-26
ATE374196T1 (de) 2007-10-15
NO20043237L (no) 2004-08-02
PA8565901A1 (es) 2003-09-05
ZA200406032B (en) 2005-10-12
DE60316538T2 (de) 2008-08-21
TWI326599B (en) 2010-07-01
NO327697B1 (no) 2009-09-14
MXPA04007516A (es) 2004-11-10
EP1474416A1 (en) 2004-11-10
US20030166639A1 (en) 2003-09-04
AU2003205695A1 (en) 2003-09-02
HK1078858A1 (zh) 2006-03-24
RU2315764C2 (ru) 2008-01-27
MY176608A (en) 2020-08-18
CN100497333C (zh) 2009-06-10
CA2474219A1 (en) 2003-08-14
AU2003205695B8 (en) 2008-05-01
AR038481A1 (es) 2005-01-19
BR0307474A (pt) 2004-11-09
JP4077411B2 (ja) 2008-04-16
WO2003066623A1 (en) 2003-08-14
HRP20040678A2 (en) 2005-10-31
DK1474416T3 (da) 2008-01-14
DE60316538D1 (de) 2007-11-08
TW200302730A (en) 2003-08-16
AU2003205695B2 (en) 2008-04-03
US6949542B2 (en) 2005-09-27
SI1474416T1 (sl) 2008-02-29
CA2474219C (en) 2010-04-13
PE20031011A1 (es) 2003-11-29

Similar Documents

Publication Publication Date Title
SI1474416T1 (sl) Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj
IL169091A0 (en) Benzazepine derivatives for the treatment of neurological disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
AU2003286567A8 (en) Methods for the treatment of skin disorders
ZA200401004B (en) Combination for the treatment of inflammatory disorders
PL1660057T3 (pl) Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
IL209842A0 (en) Compounds for the treatment of metabolic disorders
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
IL176581A0 (en) Immunomodulatory compounds for the treatment of central nervous system disorders
AP2005003274A0 (en) Thiazole compounds for the treatment of neurodegenerative disorders
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
AU2003274342A8 (en) Compositions for the treatment of autoimmune disorders
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
EP1617844A4 (en) TREATMENT OF NEUROLOGICAL DISEASES
EP1658072A4 (en) Compounds for the Treatment of Neurodegenerative Diseases
AU2003286728A8 (en) Compounds for the treatment of metabolic disorders
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
HRP20041159A2 (en) Combination for the treatment of airway disorders
GB0216097D0 (en) Treatment of proliferative disorders
AU2002322397A1 (en) Combination therapy for the treatment of neurological disorders
GB0213575D0 (en) Treatment for movement disorders

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)